Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera

Blood

Volumn 115, Issue 3, 2010, Pages 667-676

  Randi, Maria Luigia ^a   Brunati, Anna Maria ^a   Scapin, Margherita ^a   Frasson, Martina ^a   Deana, Renzo ^a   Magrin, Elisa ^a   Fabris, Fabrizio ^a   Donella Deana, Arianna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYUREA; JANUS KINASE 2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; THROMBIN; WARFARIN; JAK2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTHEMIA; WESTERN BLOTTING; ENZYME ACTIVATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE ACTIVATION; TIME;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; ENZYME ACTIVATION; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PLATELET ACTIVATION; POLYCYTHEMIA VERA; SRC-FAMILY KINASES; THROMBIN; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS;

EID: 77449127290     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-196535     Document Type: Article

References (50)

1. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
2. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
3. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106(10): 3374-3376. (Pubitemid 41609168)
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-1148. (Pubitemid 40663494)
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788-22792. (Pubitemid 40853184)
6. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005; 19(10):1847-1849. (Pubitemid 41486170)
7. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 mutation status: a prospective study. Lancet. 2005; 366(9501):1945-1953. (Pubitemid 41713984)
8. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous Jak2617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3): 840-846. (Pubitemid 47267419)
9. Antonioli E, Guglielmelli P, Poli G, et al. Influence of Jak2V617 allele burden on phenotype in essential thrombocythemia. Haematologica. 2008; 93(1):41-48.
10. Bellucci S, Michiels JJ. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4 pt 2):381-398.
11. Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005;409-415.
12. Clark EA, Brugge JS. Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets. Mol Cell Biol. 1993;13(3):1863-1871.
13. Obergfell A, Eto K, Mocsai A, et al. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol. 2002;157(2):265-275.
14. Harper MT, Sage SO. PAR-1-dependent pp60src activation is dependent on protein kinase C and increased [Ca2+]i: evidence that pp60src does not regulate PAR-1-dependent Ca2+ entry in human platelets. J Thromb Haemost. 2006;4(12): 2695-2703.
15. Ben Amor N, Bouaziz A, et al. Characterization of the intracellular mechanisms involved in the antiaggregant properties of cinnamtannin B-1 from bay wood in human platelets. J Med Chem. 2007; 50(16):3937-3944. (Pubitemid 47292057)
16. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta. 1996; 1287(2-3):121-149.
17. Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006;107(8):1918-1929.
18. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7): 2292-2302.
19. Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617Jak2 negative. Blood. 2006;108(10):3600-3602.
20. Passamonti F, Rumi E, Pietra D, et al. Relation between Jak2 (V617F) mutation status, granulocytes activation, and costitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-3682.
21. Scott L, Tong W, Levine RL, et al. Jak2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. (Pubitemid 46193073)
22. Zarpellon A, Donella-Deana A, Folda A, Turetta L, Pavanetto M, Deana R. Serotonin (5-HT) transport in human platelets is modulated by Srccatalysed Tyr-phosphorylation of the plasma membrane transporter SERT. Cell Physiol Biochem. 2008;21(1-3):87-94.
23. Brunati AM, Bordin L, Clari G, et al. Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine kinases in intact human erythrocytes: identification of primary and secondary phosphorylation sites. Blood. 2000;96(4):1550-1557. (Pubitemid 30658490)
24. Deana R, Turetta L, Donella-Deana A, et al. Green tea epigallocathechin-3-gallate inhibits platelet signaling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb Haemost. 2003;89(5):866-874. (Pubitemid 36603430)
25. Bordin L, Brunati AM, Donella-Deana A, Baggio B, Toninello A, Clari G. "Band 3 is an anchor protein and a target for SHP-2 tyrosine phosphatase in human erythrocytes" Blood. 2002;100(1):276-282. (Pubitemid 35177457)
26. Moliterno AR, Siebel KE, Sun AY, Hankins WD, Spivak JL. A novel thrombopoietin signaling defect in polycythemia vera platelets. Stem Cells. 1998;16(suppl 2):185-192.
27. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338(9):572-580. (Pubitemid 28114645)
28. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006; 108(12):3913-3915.
29. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379(6566):645-648. (Pubitemid 26053453)
30. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J. 2003;371(pt 1):199-204. (Pubitemid 36458094)
31. Hayakawa F, Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci. 2006;1086:213-222. (Pubitemid 47084370)
32. Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood. 2006;107(9):3495-3502.
33. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 2005;331(1):1-14. (Pubitemid 40545134)
34. Paling NR, Welham MJ. Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis. Blood. 2005;105(11): 4290-4297.
35. Qu CK, Nguyen S, Chen J, Feng GS. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood. 2001;97(4):911-914. (Pubitemid 32154273)
36. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92(4):441-450. (Pubitemid 28101108)
37. Yang J, Liu L, He D, et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003;278(8):6516-6520. (Pubitemid 36800913)
38. Schoenwaelder SM, Petch LA, Williamson D, Shen R, Feng GS, Burridge K. The protein tyrosine phosphatase SHP-2 regulates RhoA activity. Curr Biol. 2000;10(23):1523-1526. (Pubitemid 32003645)
39. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol. 2004;11(1):44-50.
40. Konieczna I, Horvath E, Wang H, et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest. 2008; 118(3):853-867.
41. Ugo V, Marzac C, Teysandier I, et al. Multiple signalling pathways are involved in erythroid indipendent differentation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004;32(2): 179-187. (Pubitemid 38177643)
42. Ozawa K, Kashiwada K, Takahashi M, Sobue K. Translocation of cortactin (p80/85) to the actinbased cytoskeleton during thrombin receptormediated platelet activation. Exp Cell Res. 1995; 221(1):197-204.
43. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32(6):589-604. (Pubitemid 44453020)
44. Usuki K, Iki S, Endo M, et al. Influence of thrombopoietin on platelet activation in myeloproliferative disorders. Br J Haematol. 1997;97(3):530-537. (Pubitemid 27261613)
45. Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. 2008;34(2):204-210.
46. Maxwell MJ, Dopheide SM, Turner SJ, Jackson SP. Shear induces a unique series of morphological changes in translocating platelets: effects of morphology on translocation dynamics. Arterioscler Thromb Vasc Biol. 2006;26(3):663-669.
47. Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program. 2007;363-370.
48. Rao AK. Molecular and biochemical basis for the platelet dysfunction in myeloproliferative disorders. Semin Hematol. 2004;41(2 suppl 3):6-9.
49. Kundrapu K, Colenberg L, Duhé RJ. Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. Cell Biochem Biophys. 2008;52(2):103-112.
50. Heller PG, Lev PR, Salim JP, et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol. 2006;77(3):210-216.